Blood stream infections due to multidrug-resistant organisms among spinal cord-injured patients, epidemiology over 16 years and associated risks: A comparative study

Spinal Cord

Volumn 54, Issue 9, 2016, Pages 720-725

  Dinh, A ^a   Saliba, M ^a   Saadeh, D ^b   Bouchand, F ^a   Descatha, A ^a   Roux, A L ^a   Davido, B ^a   Clair, B ^a   Denys, P ^a   Annane, D ^a   Perronne, C ^a   Bernard, L ^a,c  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^b LEBANESE UNIVERSITY   (Lebanon)

^c UNIVERSITÉ DE TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CLAVULANIC ACID; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; TICARCILLIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CATHETER INFECTION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DECUBITUS; FEMALE; HUMAN; INFECTION RISK; INJURY SEVERITY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SPINAL CORD INJURY; URINARY TRACT INFECTION; AGED; BACTEREMIA; COMPLICATION; FRANCE; LONGITUDINAL STUDY; MULTIDRUG RESISTANCE; NONPARAMETRIC TEST; SEVERITY OF ILLNESS INDEX; SPINAL CORD INJURIES;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; FRANCE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SPINAL CORD INJURIES; STATISTICS, NONPARAMETRIC;

EID: 84958793914     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2015.234     Document Type: Article

References (43)

1. National Spinal Cord Injury Statistical Center. Spinal Cord Injury Facts and Figures at a Glance 2015, National Institute on Disability and Rehabilitation: Washington, USA. Available at https://www.nscisc.uab.edu/PublicDocuments/reports/pdf/2015%20NSCISC%20Annual%20Statistical%20Report%20Complete%20Public%20Version.pdf (accessed on 21 August 2015
2. Haute Autorité de Santé. Guide Affection Longue Durée -Paraplégie (lésions médullaires) 2007
3. Wall BM, Mangold T, Huch KM, Corbett C, Cooke CR. Bacteremia in the chronic spinal cord injury population: risk factors for mortality. J Spinal Cord Med 2003; 26: 248-253
4. DeVivo MJ, Stover SL. Long term survival and causes of death. In: Stover SL, DeLisa JA, Whiteneck GG (eds). Spinal Cord Injury: Clinical Outcomes from the Model Systems. Aspen Publishers: Gaithersburg, MD, USA, 1995, pp 289-313
5. DeVivo MJ, Krause JS, Lammertse DP. Recent trends in mortality and causes of death among persons with spinal cord injury. Arch Phys Med Rehabil 1999; 80: 1411-1419
6. Darouiche RO. Infection and spinal cord injury. In: Lin VW, Cardenas DD, Cutter NC, Frost FS, Hammond MC, Lindblom LB, et al. (eds). Spinal Cord Medicine: Principles and Practice. Demos Medical Publishing, Inc.: New York, NY, USA, 2003, pp 201-220
7. Evans CT, LaVela SL, Weaver FM, Priebe M, Sandford P, Niemiec P, et al. Epidemiology of hospital-acquired infections in veterans with spinal cord injury and disorder. Infect Control Hosp Epidemiol 2008; 29: 234-242
8. Evans CT, Hershow RC, Chin A, Foulis PR, Burns SP, Weaver FM. Bloodstream infections and setting of onset in persons with spinal cord injury and disorder. Spinal Cord 2009; 47: 610-615
9. Waites KB, Canupp KC, Chen Y, DeVivo MJ, Moser SA. Bacteremia after spinal cord injury in initial versus subsequent hospitalizations. J Spinal Cord Med 2001; 24: 96-100
10. Bhatt K, Cid E, Maiman D. Bacteremia in the spinal cord injury population. J Am Paraplegia Soc 1987; 10: 11-14
11. Montgomerie JZ, Chan E, Gilmore DS, Canawati HN, Sapico FL. Low mortality among patients with spinal cord injury and bacteremia. Rev Infect Dis 1991; 13: 867-871
12. Maeder K, Ginunas VJ, Montgomerie JZ, Canawati HN. Methicillin-resistant Staphylococcus aureus (MRSA) colonization in patients with spinal cord injury. Paraplegia 1993; 31: 639-644
13. Thom JD, Wolfe V, Perkash I, Lin VW. Methicillin-resistant Staphylococcus aureus in patients with spinal cord injury. J Spinal Cord Med 1999; 22: 125-131
14. Mylotte JM, Kahler L, Graham R, Young L, Goodnough S. Prospective surveillance for antibiotic-resistant organisms in patients with spinal cord injury admitted to an acute rehabilitation unit. Am J Infect Control 2000; 28: 291-297
15. Montgomerie JZ. Infections in patients with spinal cord injuries. Clin Infect Dis 1997; 25: 1282-1285
16. Vincent JL. Nosocomial infections in adult intensive-care units. Lancet 2003; 361: 2068-2077
17. LaVela SL, Evans CT, Miskevics S, Parada JP, Priebe M, Weaver FM. Long-term outcomes from nosocomial infections in persons with spinal cord injuries and disorders. Am J Infect Control 2007; 35: 393-400
18. NCCLS. Performance Standards For Antimicrobial Susceptibility Testing. 2000, 7th edn: Approved standard M2-A7
19. Tenover FC, Raney PM, Williams PP, Rasheed JK, Biddle JW, Oliver A, et al. Evaluation of the NCCLS extended-spectrum β-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE. J Clin Microbiol 2003; 41: 3142-3146
20. Lillie PJ, Allen J, Hall C, Walsh C, Adams K, Thaker H, et al. Long-term mortality following bloodstream infection. Clin Microbiol Infect 2013; 19: 955-960
21. Rahimkhani M, Mordadi A, Varmazyar S, Tavakoli A. Evaluation of urinary interleukin-8 levels in patients with spinal cord injury. Recent Pat Antiinfect Drug Discov 2015; 9: 144-149
22. Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68: 344-355
23. Kreger BE, Craven DE, Carling PC, McCabe WR. Gram-negative bacteremia. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68: 332-343
24. Rahimkhani M, Nikfallah A, Saberian M, Mordadi A, Varmazyar S, Tavakoli A. Urinary tract infection in spinal cord injuries. Asian J Pharm Clin Res 2014; 7: 178-182
25. World Health Organization. Antimicrobial resistance. 2015. Available at http://www. who.int/mediacentre/factsheets/fs194/en/. (accessed on 1 July 2015
26. Waites KB, Chen Y, DeVivo MJ, Canupp KC, Moser SA. Antimicrobial resistance in gram-negative bacteria isolated from the urinary tract in community-residing persons with spinal cord injury. Arch Phys Med Rehabil 2000; 81: 764-769
27. Darouiche RO, Hull RA. Bacterial interference for prevention of urinary tract infection. Clin Infect Dis 2012; 55: 1400-1407
28. Mylotte JM, Graham R, Kahler L, Young L, Goodnough S. Epidemiology of nosocomial infection and resistant organisms in patients admitted for the first time to an acute rehabilitation unit. Clin Infect Dis 2000; 30: 425-432
29. Tacconelli E. New strategies to identify patients harbouring antibiotic-resistant bacteria at hospital admission. Clin Microbiol Infect 2006; 12: 102-109
30. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N Engl J Med 2010; 362: 1804-1813
31. Vogelaers D, De Bels D, Foret F, Cran S, Gilbert E, Schoonheydt K, et al. Patterns of antimicrobial therapy in severe nosocomial infections: empiric choices, proportion of appropriate therapy, and adaptation rates-a multicentre, observational survey in critically ill patients. Int J Antimicrob Agents 2010; 35: 375-381
32. Lim CJ, Cheng AC, Kennon J, Spelman D, Hale D, Melican G, et al. Prevalence of multidrug-resistant organisms and risk factors for carriage in long-term care facilities: a nested case-control study. J Antimicrob Chemother 2014; 69: 1972-1980
33. Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect 2006; 64: 7-15
34. Cordery RJ, Roberts CH, Cooper SJ, Bellinghan G, Shetty N. Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamaseproducing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome. J Hosp Infect 2008; 68: 108-115
35. Wenzel RP, Edmond MB. The impact of hospital-acquired bloodstream infections. Emerg Infect Dis 2001; 7: 174-177
36. Weinstein MP, Murphy JR, Reller LB, Lichtenstein KA. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. Clinical observations, with special reference to factors influencing prognosis. Rev Infect Dis 1983; 5: 54-70
37. Guo B, Abdelraouf K, Ledesma KR, Nikolaou M, Tam VH. Predicting bacterial fitness cost associated with drug resistance. J Antimicrob Chemother 2012; 67: 928-932
38. Luciani F, Sisson SA, Jiang H, Francis AR, Tanaka MM. The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2009; 106: 14711-14715
39. Martínez JL, Baquero F. Interactions among strategies associated with bacterial infection: pathogenicity, epidemicity, and antibiotic resistance. Clin Microbiol Rev 2002; 15: 647-679
40. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrugresistant Pseudomonas aeruginosa: epidemiology and treatment options. Pharmacotherapy 2005; 25: 1353-1364
41. Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis 2008; 46: 1121-1122
42. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55: 1619-1629
43. Hachem RY, Chemaly RF, Ahmar CA, Jiang Y, Boktour MR, Rjaili GA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother 2007; 51: 1905-1911